Clinical News

Select Clinical Trials Currently Enrolling Patients with Melanoma

June 2017, Vol 7, No 6 - Clinical Trials Tracker

The following clinical trials represent a selection of key studies that are currently recruiting patients with melanoma for inclusion in investigations of new therapies or new regimens of existing treatments for patients with melanoma. Each description includes the NLM Identifier to be used as a reference with ClinicalTrials.gov. This information can help oncology practice managers and providers direct eligible patients to an appropriate clinical trial. [ Read More ]

Select Clinical Trials Currently Enrolling Patients with Brain Cancer

May 2017, Vol 7, No 5 - Clinical Trials Tracker

The following clinical trials represent a selection of key studies that are currently recruiting patients with brain cancer for inclusion in investigations of new therapies or new regimens of existing treatments for patients with brain cancer. Each description includes the NLM Identifier to be used as a reference with ClinicalTrials.gov. This information can help oncology practice managers and providers direct eligible patients to an appropriate clinical trial. [ Read More ]

Zejula a New Maintenance Treatment Option for Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

May 2017, Vol 7, No 5 - FDA News

On March 27, 2017, the FDA accelerated the approval of niraparib (Zejula; Tesaro), a PARP inhibitor, for maintenance treatment of 3 types of cancers—recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer—in adults who had a complete or partial response to platinum-based chemotherapy. [ Read More ]

FDA News – April 2017

April 2017, Vol 7, No 4 - FDA News

  • Keytruda Receives Accelerated Approval for Relapsed/Refractory Classical Hodgkin Lymphoma
  • Kisqali, a New CDK4/CDK6 Inhibitor, Approved as First-Line Therapy for HR-Positive, HER2-Negative Advanced Breast Cancer
  • Xermelo First Oral Treatment Approved for Carcinoid Syndrome Diarrhea in Patients with NETs
  • Revlimid Approved as Maintenance Therapy for Multiple Myeloma After Autologous Stem-Cell Transplantation
  • Opdivo Now Approved for Advanced or Metastatic Bladder Cancer
  • Imbruvica First Nonchemotherapy Drug Approved for Relapsed/Refractory Marginal Zone Lymphoma
  • Rubraca a New Treatment Option for Patients with Advanced Ovarian Cancer
[ Read More ]

Select Clinical Trials Currently Enrolling Patients with Multiple Myeloma

March 2017, Vol 7, No 3 - Clinical Trials Tracker

The following clinical trials represent a selection of key studies that are currently recruiting patients with multiple myeloma for inclusion in investigations of new therapies or new regimens of existing treatments for patients with multiple myeloma. Each description includes the NLM Identifier to be used as a reference with ClinicalTrials.gov. This information can help oncology practice managers and providers direct eligible patients to an appropriate clinical trial. [ Read More ]

Lenvima (Lenvatinib) Approved in Combination with Everolimus for Patients with Advanced Renal-Cell Carcinoma

Loretta Fala

February 2017, Vol 7, No 2 - Drug Update

Approximately 394,336 Amer­icans were living with kidney cancer in 2013. In 2016 alone, an estimated 62,700 people were diagnosed with kidney cancer, and 14,240 people died from the disease. Renal-cell carcinoma (RCC), the most common type of kidney cancer, accounts for 85% to 90% of new cases of the disease. More than 70% of kidney cancers are clear-cell tumors—named for the clearness (or paleness) of the cells when viewed under a microscope. [ Read More ]

Select Ongoing Trials Currently Enrolling Patients with Renal-Cell Carcinoma

February 2017, Vol 7, No 2 - Clinical Trials Tracker

The following studies represent a selection of key clinical trials that are currently recruiting patients with renal-cell carcinoma (RCC) for inclusion in investigations of new therapies or new combinations of available ther­apies for patients with kidney cancer. Each trial description includes the NLM Identifier to be used as a reference with ClinicalTrials.gov. The information below can help oncology practice managers and providers direct their eligible patients to one of these clinical trials. [ Read More ]

FDA News – January 2017

January 2017, Vol 7, No 1 - FDA News

In This Article Rubraca Approved for Advanced Ovarian Cancer with BRCA Mutations Avastin Approved for Platinum-Sensitive Ovarian Cancer Darzalex Approved for Use in Combination with Standard Regimen for Multiple Myeloma Opdivo Now Approved for Head and Neck Squamous-Cell Carcinoma Rubraca [ Read More ]